Clinical trial
Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
NCT00110591 · CytoDyn, Inc., Industry · Completed
Key facts
| NCT number | NCT00110591 |
|---|---|
| Title | Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers |
| Official title | A Phase I, Randomized, Double Blind, Placebo Controlled, Single-Dose, Rising Dose Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO 140 in Healthy Volunteers |
| Lead sponsor | CytoDyn, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | PRO 140 |
| Enrollment | 20 |
| Start date | Apr 16, 2004 |
| Primary completion | Nov 7, 2005 |
| Completion | Mar 31, 2008 |
| First posted | May 11, 2005 |
| Last update posted | Mar 14, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: